Extended Dual Antiplatelet Therapy After Acute Coronary Syndrome in Spain: Results from the EPICOR Study

ConclusionsMore than half of patients in this unselected cohort study remained on DAPT at 2 years following discharge for ACS. Continuation with DAPT was greater among patients with additional cardiovascular risk factors, which suggests that treating physicians in Spain prioritize ischemic risk reduction over bleeding risk in ACS patients, according to patient risk profile.
Clinical Trial Registration—URLhttp://www.clinicaltrials.gov. Unique identifier: NCT01171404.This article is protected by copyright. All rights reserved.

Source: Cardiovascular Therapeutics - November 25, 2016 Category: Cardiology Authors: Alfredo Bardaj í, Manuel Leal, Vicente Arrarte, Xavier Garcia‐Moll, Leopoldo  Pérez de Isla, Héctor Bueno Tags: Original Research Article Source Type: research